This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through October 6, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
medical: Archive
Will Cobenfy Become a Growth Driver for BMY's Neuroscience Business?
by Ekta Bagri
Bristol Myers Squibb moves forward with its ADEPT-2 study on Cobenfy, delaying data to next year but boosting investor sentiment.
BIIBNegative Net Change BMYNegative Net Change LLYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Can UNH's AI-Powered Virtual Assistance Enhance Member Experience?
by Zacks Equity Research
UnitedHealth's AI-powered virtual assistants aim to simplify claims, boost engagement and deliver faster, more intuitive healthcare support.
UNHNegative Net Change HUMNegative Net Change ELVNegative Net Change
artificial-intelligence insurance medical
PRAX Stock Skyrockets 520% in 3 Months: Here's What You Need to Know
by Zacks Equity Research
Praxis stock soars after late-stage data show strong efficacy for ulixacaltamide therapy in essential tremor and momentum builds toward an early-2026 regulatory filing.
ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change PRAXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Incyte's Rare Blood Cancer Therapy Gets FDA's Breakthrough Status
by Zacks Equity Research
INCY secures FDA Breakthrough Therapy status for INCA033989 after early data show rapid and sustained platelet normalization in essential thrombocythemia patients.
INCYNegative Net Change ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
CONMED Stock Falls as It Strategically Exits Gastroenterology Portfolio
by Zacks Equity Research
CNMD is set to exit its gastroenterology portfolio to streamline its focus on higher-growth surgical platforms and boost long-term margins.
BSXNegative Net Change CNMDPositive Net Change ISRGNegative Net Change MEDPPositive Net Change
medical medical-devices
Tempus AI: Data Flywheel and MRD Expansion Reshape the Outlook
by Urmimala Biswas
Tempus AI's data engine, MRD buildout and ADLT milestones set the stage for faster growth while profitability metrics turn the corner.
ILMNNegative Net Change GHPositive Net Change TEMPositive Net Change
artificial-intelligence earnings-report healthcare medical medical-devices
Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties
by Swayta Shah
Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.
ILMNNegative Net Change NEMNegative Net Change CMCNegative Net Change
basic-materials medical
HOLX Stock Up 16% in 6 Months: Is it Still a Hold Heading Into 2026?
by Moumi Mondal
Hologic shares rise 16% in six months, with divisional strength clinical data and a go-private deal shaping the short-term outlook.
ABTNegative Net Change HOLXNegative Net Change QGENNegative Net Change
medical medical-devices
3 Generic Drug Stocks to Watch Amid Changing U.S. Landscape
by Sundeep Ganoria
Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.
RDYNegative Net Change TEVANegative Net Change SDZNYPositive Net Change
medical
Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus
by Abhinab Dasgupta
Veracyte, Las Vegas Sands and 3M shine as Zacks spotlights standout stock gains and portfolio wins amid shifting market sentiment.
KOPositive Net Change AMGNNegative Net Change MMMNegative Net Change MUPositive Net Change TMONegative Net Change LRCXPositive Net Change LVSPositive Net Change AUNegative Net Change FOLDNegative Net Change MTZPositive Net Change VCYTNegative Net Change
consumer-discretionary medical precious-metals
ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?
by Indrajit Bandyopadhyay
Intuitive Surgical's golden crossover arrives amid surging procedures and rapid dV5 adoption, raising the stakes for its bullish momentum.
MDTNegative Net Change SYKNegative Net Change ISRGNegative Net Change
medical medical-devices
PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements
by Zacks Equity Research
Insulet Stock rises as the FDA clears key Omnipod 5 upgrades that enhance glucose targets and automation for its tubeless diabetes platform.
OMCLPositive Net Change ILMNNegative Net Change PODDNegative Net Change BTSGNegative Net Change
medical
Best Value Stocks to Buy for December 8th
by Zacks Equity Research
GM, CRMD and AER made it to the Zacks Rank #1 (Strong Buy) value stocks list on December 8, 2025.
GMNegative Net Change AERNegative Net Change CRMDPositive Net Change
auto-tires-trucks medical transportation
New Strong Sell Stocks for December 8th
by Zacks Equity Research
AKR, AVTR and CRI have been added to the Zacks Rank #5 (Strong Sell) List on December 8, 2025.
AKRNegative Net Change CRINegative Net Change AVTRNegative Net Change
consumer-discretionary medical reit
New Strong Buy Stocks for December 8th
by Zacks Equity Research
VFF, CRMD, AER, GM and FIVE have been added to the Zacks Rank #1 (Strong Buy) List on December 8, 2025.
GMNegative Net Change FIVEPositive Net Change AERNegative Net Change CRMDPositive Net Change VFFNegative Net Change
auto-tires-trucks consumer-staples medical retail transportation
BD Stock Up Post Tie-Up to Expand Hazardous Drug Contamination Testing
by Zacks Equity Research
BDX teams up with ChemoGLO to expand hazardous drug testing, aiming to boost safety in healthcare environments.
BDXNegative Net Change ISRGNegative Net Change CAHPositive Net Change SOLVNegative Net Change
medical medical-devices
GEHC Forms 7-Year Care Alliance to Advance URMC Imaging & Monitoring
by Zacks Equity Research
GE HealthCare's seven-year alliance with URMC advances imaging, precision medicine and system-wide monitoring upgrades across UR Medicine.
BSXNegative Net Change ISRGNegative Net Change MEDPPositive Net Change GEHCNegative Net Change
medical medical-devices
ABSI Stock Up on Initiating Dosing in Androgenetic Alopecia Study
by Zacks Equity Research
Absci Corporation stock jumps after initiating dosing in its phase I/IIa ABS-201 study for androgenetic alopecia, seeking early safety and efficacy signals.
ANIPNegative Net Change CRMDPositive Net Change ARQTNegative Net Change ABSINegative Net Change
biotechnology biotechs medical pharmaceuticals
CAPR Stock Skyrockets 282% in a Week: Here's What You Need to Know
by Zacks Equity Research
Capricor Therapeutics stock soars after meeting key goals with statistical significance in a phase III study of deramiocel for Duchenne cardiomyopathy.
ANIPNegative Net Change CRMDPositive Net Change CAPRPositive Net Change ARQTNegative Net Change
biotechnology biotechs medical pharmaceuticals
Denali Enters Into a $275M Funding Deal With Royalty Pharma
by Ekta Bagri
DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.
BIIBNegative Net Change RPRXNegative Net Change DNLINegative Net Change TAKPositive Net Change
biotechnology biotechs medical pharmaceuticals
4 Stocks Trading Near 52-Week High With Room to Rise Further
by Vasundhara Sawalka
Investors target stocks that have been on a bullish run. Stocks like KSS, HRTG, MD and NEM are seeing price strength, and the momentum is likely to continue.
KSSNegative Net Change NEMNegative Net Change MDNegative Net Change HRTGPositive Net Change
basic-materials finance medical retail
Will Breyanzi's Label Expansion Boost BMY's CAR T Cell Therapy Sales?
by Ekta Bagri
Bristol Myers gains FDA approval to expand Breyanzi's label to R/R marginal zone lymphoma, strengthening its CAR T portfolio amid rising sales.
NVSNegative Net Change BMYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals
Tempus AI: Revenue Mix and 2026 Growth Outlook Explained
by Urmimala Biswas
Tempus AI's balanced genomics and data engine is scaling fast as profitability metrics improve and 2026 revenue targets approach the billion-plus mark.
EXASNegative Net Change GHPositive Net Change TEMPositive Net Change
healthcare medical medical-devices oncology-screening
COO Gains as Q4 Earnings & Sales Beat Estimates, MyDay Adoption Rises
by Zacks Equity Research
COO jumps after Q4 earnings and sales top estimates, powered by rising MyDay demand and strong MiSight momentum.
ISRGNegative Net Change COONegative Net Change MEDPPositive Net Change SGHTPositive Net Change
earnings medical medical-devices
Here's Why You Should Add Inogen Stock to Your Portfolio Now
by Zacks Equity Research
INGN gains momentum from rising POC demand, new product launches and strong Q3 sales, even as competition and forex swings temper near-term growth.
ISRGNegative Net Change INGNNegative Net Change MEDPPositive Net Change SGHTPositive Net Change
medical medical-devices